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Objective scoring systems of medical risk:
A clinical tool for selecting patients for open
or endovascular abdominal aortic aneurysm repair
Rumi Faizer, MD,a Guy DeRose, MD,b D. Kirk Lawlor, MD,b Kenneth A. Harris, MD,b and
Thomas L. Forbes, MD,b Columbia, Mo; and London, Ontario, Canada
Background:Objective scoring systems have been developed for risk stratification of open infrarenal aneurysm repair. To
date, none have been applied for the selection of patients who would most benefit from either an open or an endovascular
approach. This study assessed the utility of comorbidity-based objective scoring systems for defining subgroups of
patients who might most benefit from open or endovascular aneurysm repair.
Methods: A retrospective database review was performed for the period January 1999 to December 2004 to identify
patients who had undergone elective open aneurysm repair (open repair) or elective endovascular aneurysm repair
(EVAR). Validation of the Glasgow Aneurysm Score (GAS), the Modified Leiden Score (M-LS), and the Modified
Comorbidity Severity Score (M-CSS) was performed for perioperative mortality risk in the open repair group. GAS,
M-LS, and M-CSS were then calculated for the EVAR group. Differences in open repair vs EVAR mortalities were
evaluated.
Results: During the time period, 558 patients underwent open repair and 304 underwent EVAR. Overall mortality
was 4.7% for open repair patients and 2.0% for EVAR. All three scoring systems were validated to our open repair
data set (C statistic: GAS, 0.72; M-LS, 0.71; M-CSS, 0.74). A score was calculated for each system that separated
patients into groups of either low or high risk of death for open repair. This score (cut point) was 76.5 for the GAS,
5.2 for the M-LS, and 8 for the M-CSS. Analysis of the EVAR population revealed that patients at low medical risk
for open repair did not derive statistically significant mortality benefit with EVAR; however, patients at high medical
risk for open repair derived significant benefit from EVAR (GAS >76.5 mortality: open repair, 7.8%; EVAR, 1.9%
[P < .01]; M-LS mortality: open repair, 8.1%; EVAR, 2.5% [P < .01]; and M-CSS mortality: open repair, 10.3%;
EVAR, 3.4% [P < .025]). Despite a very small number of deaths (n  6), receiver operator curve analysis identified
M-LS and M-CSS as having some predictive ability for mortality risk with EVAR (C statistic: M-LS, 0.70;
M-CSS, 0.69).
Conclusion: Three validated objective scoring systems can be used to categorize patients into two groups of medical risk:
one that has excellent outcome with open repair and derives no early mortality benefit from EVAR, and another that has
significant mortality with open repair and derives important benefit with EVAR. (J Vasc Surg 2007;45:1102-8.)Open aneurysm repair (open repair), is recommended
for patients whose risk of rupture exceeds the risk of peri-
operative mortality.1 Several medical risk-stratification sys-
tems have been developed to further define the risk of
perioperative death for a given patient. Numerous validated
models have identified subgroups of patients with exceed-
ingly low as well as unacceptably high perioperative mor-
tality. One such model, the Glasgow Aneurysm Score
(GAS), has been validated as part of an open aneurysm
repair outcomes analysis at our institution.2 To date the
overall recommendations from validations of such models
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1102have been limited to suggesting that open operations be
cautiously examined in higher-risk patients.
Endovascular aneurysm repair (EVAR) has a proven
lower perioperative risk than open repair.3 Unfortunately,
randomized data suggest that this early benefit is lost by the
fourth year of follow-up.4 The long-term need for close
surveillance and important rates of reintervention therefore
call into question the appropriateness of EVAR in good-
risk patients with a significant life expectancy. Unfortu-
nately, randomized studies in high-risk patients also lay
doubt on the appropriateness of EVAR for patients who are
too high risk for open repair.5
Our hypothesis is that there exists an objectively
definable medical risk subgroup for whom open repair
can be performed with such low perioperative mortality
that the purported early mortality benefits of EVAR are
invalid. Furthermore, another subgroup may be defined
for whom open repair carries a much higher-than-average
risk, but for whom EVAR mortality is low. To date no
studies, to our knowledge, have objectively quantified
risk strata by choice of aneurysm repair. The aim of this
study was to assess the utility of comorbidity-based
objective scoring systems for defining subgroups of pa-
ure; M
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EVAR.
METHODS
The database at our university-affiliated medical center
consists of prospectively collected information on all major
vascular surgeries performed by one of four surgeons. It
contains patient demographic data, intervention modality,
outcome, and specific grading of a number of medical risk
factors as defined by the Ad Hoc Committee on Reporting
Standards of the Society for Vascular Surgery (SVS) (Ap-
pendix 1, online only).6 This database was retrospectively
reviewed for elective open and endovascular aneurysm re-
pairs performed from January 1999 to December of 2004.
The primary outcome variable wasmortality30 days of an
elective infrarenal aneurysm repair. The analysis was per-
formed as intention to treat.
Operative repair. Aneurysm repair was performed for
abdominal aortic aneurysms (AAAs)5.5 cm diameter. All
repairs were performed by one of four surgeons. Three of
the four regularly performed both open and EVAR repair.
The fourth performed open repair exclusively. The decision
for EVAR was usually based on a perception of increased
risk for open repair. This was not prospectively subjected to
a propensity analysis.
Open surgeries were almost uniformly performed
through midline incision with an anterior transperitoneal
approach. EVAR repair was performed in the operating
room by using portable C-arm fluoroscopy and Vanguard
(Boston Scientific, Natick, Mass, used in the first year),
Zenith (Cook, Bloomington, Ind), and Talent (Medtronic,
Santa Rosa, Calif) endografts. Bifurcated endografts were
used in 26% of cases, aortouniiliac endografts in 66%, and
aortoaortic endografts in 8% of our initial cases.
Scoring system. Several scoring systems were applied
to our patient database (Table I).
Glasgow Aneurysm Score. The GAS7 is a scoring
system of operative risk that has been validated in multiple
elective open repair populations.8-10 It includes variables
for age, coronary artery disease (CAD), cerebrovascular
disease (CVD), and renal failure. It also included the vari-
able of shock in its original form, but this has been omitted
by all validations for elective surgery. CAD is defined
loosely as any history of cardiac disease, whether intervened
Table I. Scoring system formulas
Scoring system
Glasgow Aneurysm Score Age  7 if CAD  1
Leiden Score (raw) (Age-70)/2.5  4 if
ischemia  12 if R
Leiden Score (% mortality calculation)  10/{1  EXP [(
Comorbidity Severity Score 4  cardiac status 
status (0 if 55, 1
CAD, Coronary artery disease; CVD, cerebrovascular disease; RF, renal fail
electrocardiogram; COPD, chronic obstructive pulmonary disease; EXP, exupon or not. CVD is likewise defined as any history oftransient or permanent neurologic event. Renal failure was
modified for our study from a definition of history of acute
or chronic renal failure or serum creatinine value 1.7
mg/dL (150 mmol/L), or both, or a blood urea nitrogen
(BUN) value of 56 mg/dL (20 mmol/L) to a serum
creatinine value of 1.5 mg/dL (135 mmol/L), or both,
without consideration of BUN (Appendix 2, online only).
Omission of BUN from the definition of renal failure was
used in a previously published validation.9
Leiden Scoring System. The Leiden Scoring System
for perioperative risk with open aneurysm repair11 has been
validated in two populations.10,12 It is calculated by using the
variables of age, sex, history of myocardial infarction (MI),
congestive heart failure (CHF), electrocardiographic (ECG)
evidence of ischemia, renal failure, and pulmonary disease
(COPD). Once the raw score is calculated, the Leiden Score
authors implemented a conversion algorithm to directly pre-
dict expected perioperative mortality in percent (Table I). The
authors also outline an additional standardization adjustment
based on actual overall mortality for elective aneurysm repair
in the population being investigated (not shown).
Multiple changes to the Leiden score calculation were
made for our study. In our database, ECG evidence of
ischemia was not recorded as such but was generally defined
as stable angina. This definition was also grouped with
compensated CHF. As a result, patients could not be
scored separately for stable angina and CHF. This reduced
the number of variables from seven to six. A similar simpli-
fication has been used in a previous validation of this
scoring system.12 As with the GAS, renal failure was mod-
ified from a definition of serum creatinine of 1.8 mg/dL
(160 mmol/L) to a definition of serum creatinine 1.5
mg/dL (135 mmol/L) (Appendix 2, online only). Modi-
fications to the absolute cut off for creatinine have been
used in other published validations.12
To simplify data interpretation, raw scores (without the
conversion factor) were reported and used for statistical
analysis. Because of the changes in definition of disease and
as well as the reporting of raw scores, the applied score was
referred to as the Modified Leiden Score (M-LS).
Comorbidity Severity Score. The Ad Hoc Commit-
tee for Standardized Reporting Practices in Vascular Sur-
gery of the SVS/American Association for Vascular Surgery
has published a proposed scoring system for use with
Formula
VD  14 if RF
le  3 if prior MI  8 if Hx of CHF  8 if ECG evidence of
if COPD
en raw score)/10}  6.14)]}
ulmonary status  2  renal status  hypertension status  age
to 69, 2 if 70 to 79, 3 if 80)
I, Myocardial infarction; Hx, history; CHF, congestive heart failure; ECG,
tial.0 if C
fema
F  7
{Leid
2  p
if 55EVAR.13 This scoring system incorporates two compo-
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factor severity score. For the purposes of our study, we
assessed only the comorbidity severity component in our
patient population. The components of the CSS are cardiac
disease, pulmonary disease, renal disease, hypertension, and
age. Each component is graded with a score from 0 to 3
based on clinical parameters defined by the SVS (Appendix 3,
online only). Scores for each component are then weighted
with an emphasis on cardiac disease.
Our database was defined using the original SVS crite-
ria for risk factor definition first published in 1986.6 It was
therefore possible to apply the CSS directly to our data. The
risk factor definitions were updated in 1997 to specifically
include objective testing such as dipyridamole thallium scan
findings.14 Our database does not include these revisions;
however, it was likely that objective test results were con-
sidered when classifying a patient’s comorbidities. Because
of the differences between the 1986 and 1997 definitions,
the applied scoring system was referred to as the Modified
Comorbidity Severity Score (M-CSS).
Validation of open repair population. Scores were
calculated for each patient undergoing open repair by each
of the three scoring systems. The validity of each systemwas
assessed in several ways. Patients were grouped into quar-
tiles of risk for each scoring system. Differences in risk of
Table II. Patient demographics
Open repair
N (%)
EVAR
No (%)
Patients 558 304
Female 105 (18.8) 42 (13.8)
Asymptomatic CAD* 220 (39.4) 55 (18.1)
Compensated CHF/stable angina* 95 (17) 159 (52.3)
COPD* 65 (11.6) 136 (44.7)
CRF 11 (2) 7 (2.3)
CVD 12 (2.2) 9 (3)
Hypertension 480 (86) 261 (85.9)
Average age (years)* 71 75
Deaths 26 (4.7) 6 (2)
EVAR, Endovascular aneurysm repair; CAD, coronary artery disease; CHF,
congestive heart failure; COPD, chronic obstructive pulmonary disease;
CRF, chronic renal failure; CVD, cerebrovascular disease.
*Significant.
Table III. Univariate analysis of comorbidities
Risk factor RR (95% CI) P
Male sex 5.8 (1.03-33.8) .05
Asymptomatic CAD 3.2 (1.29-8.24) .025
CHF/angina 3.04 (1.44-6.38) .01
COPD 1.40 (0.01-3.41) NS
CRF 2.1 (0.57-7.00) NS
CVD 0.81 (0.14-4.25) NS
Hypertension 0.71 (0.29-1.80) NS
Age 70 5.5 (1.75-17.5) .01
RR, Relative risk;CI, confidence interval;CAD, coronary artery disease;CHF,
congestive heart failure;COPD, chronic obstructive pulmonary disease;NS, not
significant; CRF, chronic renal failure; CVD, cerebrovascular disease.death for each quartile were assessed for significance by 2analysis. Also performed was a logistic regression analysis
with outcome of death in which the scoring system was
used as the independent variable. An assessment of calibra-
tion of goodness of fit of each scoring system for predicting
deathwas assessedbyHosmer-Lemeshow testing.Receiver-
operator curve (ROC) analysis was used to assess discrimi-
native ability of the risk models in this patient population by
C statistic calculation and to assign dichotomous cut-point
values of increased risk of perioperative mortality.
Application to endovascular aneurysm repair popula-
tion. The quartiles of risk associated with the open repair
data were then applied to the EVAR population. Differ-
ences in observed vs predicted mortality were assessed for
significance by the Fisher exact test. Dichotomous cut
points from open repair data were also applied to the EVAR
group to compare predicted vs observed mortality. These
dichotomous groupings were also compared by 2 because
of adequate sample size. ROC analysis was performed on
the EVAR data to calculate a C statistic and define cut
points for increased operative risk with EVAR.
RESULTS
During this 6-year period, 862 patients underwent
repair: 558 had open repair and 304 had EVAR. Demo-
graphic information is listed in Table II. EVAR patients
tended to be older (average 75 vs 71) and had a higher
incidence of CHF or angina (52% vs 17%), any coronary
disease (70% vs 56%), and COPD (45% vs 12%).
Univariate analysis of association of individual risk
factors with mortality risk in the open repair data set
identified age, grade I CAD (asymptomatic heart dis-
ease), grade II CAD (compensated CHF or stable an-
gina), and male gender as statistically significant risks
(Table III). Four patients crossed over from the EVAR
group to open repair, all within the first 2 years. Success
of EVAR was 300 (98.7%) in 304 patients. None died
within the perioperative period for either intervention.
No patients were converted from open repair to EVAR.
Application of the scoring systems to our open repair
Fig. Open aneurysm repair mortality with quartiles of risk by
scoring system. GAS, Glasgow Aneurysm Score; M-LS, Modified
Leiden Score; M-SVS, Modified Society of Vascular Surgery Co-
morbidity Severity Score.population showed that all three scoring systems were
terval;
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significantly increased risk of perioperative mortality
(Fig, Table IV). Logistic regression analysis also revealed
a highly significant association between death and in-
creased score for each of the scoring systems (P  .001
for GAS, P .001 for M-LS, and P .0001 for M-CSS).
Hosmer-Lemeshow goodness-of-fit testing supported
this association for each of the three scoring systems.
Application of ROCs to the data revealed an area
under the curve (C statistic) of 0.72 for GAS, 0.71 for
M-LS, and 0.74 for the M-CSS (Table V). Cut points
were also identified that allowed dichotomous definition
of groups at a statistically different risk of perioperative
mortality for each of the scoring systems (Table VI).
Application of the same scoring systems to our EVAR
population revealed that EVAR patients were signifi-
cantly higher-risk patients as defined by each of the
scoring systems (average GAS, 81.0 vs 76.4; average
M-LS, 10.7 vs 5.3; average M-CSS, 8.9 vs 6.9). When
the quartiles of risk that had been defined for the open
repair population were applied to the EVAR population,
observed mortality was clearly different (Table IV). This
difference, however, was only statistically significant for
the highest risk quartiles (GAS83, M-LS8.6, M-CSS
9). Application of the cut points identified through
open repair ROCs showed highly significant reductions
in observed mortality for high-risk patients treated with
EVAR (Table VI).
ROC curves were also created directly from the
EVAR data set. Predictive ability (C statistic) for the
scoring systems for mortality was lower for the EVAR
population (Table V); however, the M-LS and the M-
CSS appeared to generate some predictive ability. Cut
points were 11.8 for the M-LS and 9 for the M-CSS in
the EVAR population. Mortalities above and below
these cut points were 0.6% and 3.9% (P  0.05) for the
Table IV. Comparison between open repair and endovasc
Score quartiles Open mortality (%)
Glasgow Aneurysm Score
70 0.70
70-77 2.80
77-83 6.90
83 8.50
Modified Leiden Score
1.8 0.70
1.8-5.0 2.10
5.2-8.4 6.70
8.4 9.20
Modified Comorbidity Severity Score
0-3 0
4-6 2.80
7-8 4.30
8 10.20
EVAR, Endovascular aneurysm repair; RR, Relative risk; CI, confidence inM-LS, and 0% and 3.73% for the M-CSS (P  0.025).DISCUSSION
The vascular community has accepted endovascular
treatment of AAAs as an option that trades uncertain long-
term durability and increased overall cost for decreased
perioperative surgical risk. However, currently no clear
guidelines are available to objectively define when this
trade-off is medically justified. Published randomized
trials of EVAR vs open repair loosely defined “good risk”
as a patient who could be considered “medically well
enough for elective” surgery, but did not consider al-
ready available stratification systems for objectively de-
fining risk with open repair.1 As a result, perioperative
mortality in the open repair group closely resembles that
seen with pooled data for open repair in all comers on a
national or nonselected level.15 This situation leaves
room for stricter definition.
The first step was to choose a stratification system.
From a practical standpoint, scoring systems were chosen
that used elements already recorded in our aneurysm data-
base. The GAS was chosen because of its simplicity and its
track record of validity.8-10 The Leiden scoring system,
although fairing no better than the GAS in a comparative
validation of multiple scoring systems,10 is compelling be-
cause of its increased weighting of major CAD in the form
repair outcomes using open repair defined quartiles
EVAR mortality (%) RR (95% CI) P
0 N/A NS
3.30 0.85 (0.19-3.92) NS
2.40 2.95 (0.75-11.90) NS
1.60 5.25 (1.34-20.98) .02
0 N/A NS
0 N/A NS
0 N/A NS
3.00 3.03 (1.22-7.59) .015
0 N/A NS
0 N/A NS
0 N/A NS
3.40 2.98 (1.23-7.33) .01
NA, not applicable.
Table V. Cut-point analysis of open aneurysm repair and
endovascular repair data sets
Repair Scoring system C stat Cut point Sensitivity Specificity
Open GAS 0.72 76.5 88.5 49.1
M-LS 0.71 5.2 84.6 53.4
M-CSS 0.74 8 57.7 75.4
EVAR GAS 0.47 70.9 100 13.1
M-LS 0.7 11.8 83.3 57.9
M-CSS 0.69 9 100 42.9
GAS, Glasgow Aneurysm Score; M-LS, Modified Leiden Score; M-CSS,
Modified Comorbidity Severity Score.ularof CHF or ECG changes suggesting angina. Given that in
terval;
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postoperative mortality and major morbidity and weighs
considerably into our clinical decision-making against open
repair, it was included in this analysis.
As outlined, our database did not allow for distinction
between patients who had ECG changes of ischemia and
those with compensated CHF. It is recognized that this
modification will score patients with both CHF and ECG
evidence of ischemia too low. This scoring system was
initially developed with a complex algorithm to convert the
score to an absolute predicted risk of death in percent open
repair. However, we chose to report our data with raw
Leiden scores because this allows for rapid calculation in a
clinical setting and avoids mathematical dilution of results.
Of interest was that applying the conversion factor to our
data revealed remarkable congruity between expected and
observed mortalities; for example, patients with an ex-
pected mortality of 2% to 5% by Leiden score actually had a
mortality of 3.8% in our open repair population (Appendix 4,
online only).
The SVS’s CSS was also applied to our data set. It was
assessed because it is the only stratification system that was
specifically intended for EVAR risk stratification. To our
knowledge, this is the first attempt at validation of this
scoring system.
Our quartile data for open repair show that all three
scoring systems are highly valid in our patient population.
The receiver-operator curves echo this finding. The area
under the curve (C statistic) for each of these scoring
systems compares well with that observed in other pub-
lished validations.9 It is interesting that the M-CSS per-
formed at least as well as the validated scoring systems for
stratification of our open repair population (C statistic:
0.74 vs 0.72 for GAS and 0.71 for M-LS).
When each of the scoring systems is applied to our
EVAR population, several points are worthy of note. For
the highest quartile of risk with open repair, statistically
significant reductions in mortality were clearly observed for
EVAR with all scoring systems. For any given degree of
medical risk, regardless of stratification system used, no
patient was at statistically significantly higher risk with
EVAR than with open repair.
These validated scoring systems offer an objective
Table VI. Comparison between open repair and endovasc
Score Open mortality
Glasgow Aneurysm Score
76.5 1.1
76.5 7.8
Modified Leiden Score
5.2 1.4
5.2 8.1
Modified Comorbidity Severity Score
76.5 2.7
76.5 10.3
EVAR, Endovascular aneurysm repair; RR, Relative risk; CI, confidence in
*Significance set at P  .05.means to assess risk of death from open repair and EVARfor a given patient. As such, they may be used as tools for
choosing between surgical options. This decision is facili-
tated by use of cut-point values that can be derived from the
ROCs (Table IV). Patients with scores below the cut points
for the open repair data have a very low risk of mortality
with open repair. This is perhaps less true with use of the
M-CSS (2.7%mortality vs 1.1% as defined byGAS and 1.4%
with M-LS). Patients with scores above these cut points
have a much higher mortality with open repair but a low
mortality with EVAR overall: GAS 76.5 has open repair
mortality of 7.8% vs 1.9% with EVAR,M-LS5.2 has open
repair mortality of 8.1% vs 2.5% with EVAR, and M-CSS
has open repair mortality of 10.2% vs 3.4% with EVAR. All
three of the systems are simple to calculate, but the GAS is
certainly the most user friendly. Given that it cedes little to
the other scoring systems in comparing open repair risk
with EVAR risk, it would likely be the objective scoring
system of choice.
Despite a small number of deaths in our EVAR group,
both the M-LS and the M-CSS appear to have predictive
ability with EVAR that is similar to that seen in some
reports with open repair (C statistic is 0.70 for M-LS and
0.69 for M-CSS).9,12 Mortalities with these stratification
systems were only seen in patients in the highest stratum. In
our EVAR patient population, the GAS showed poor strat-
ification of risk of death (C statistic, 0.47). This is contrary
to the observation of the European Collaborators on Stent-
Graft Techniques for AAA and Thoracic Aortic Aneurysm
and Dissection Repair (EUROSTAR) investigators, who
found the GAS to be predictive of mortality when applied
retrospectively to their far larger database (C statistic,
0.70).16 It is probable that our database is simply not large
enough to corroborate the validity of the GAS in EVAR.
Consideration of patients who might be high risk for
EVAR brings about a more complex algorithm. A recent
analysis of theUnited States Investigational Device Exemp-
tion (US IDE) trials showed that patients with major
comorbidities could undergo EVAR with a relatively low—
but higher than baseline—mortality of 2.9%.17 The EVAR-2
trial has shown us that there is no overall mortality benefit of
EVAR over observation in a fragile cohort, whose periopera-
tive mortality with EVAR was 9%.5 The EUROSTAR data-
base identified tertiles of risk with EVAR using the GAS.16
repair outcomes using open repair defined cut points
EVAR mortality RR (CI) P
2.2 0.52 (0.10-2.57) NS
1.9 4.17 (1.54-11.45) .01*
0 n/a NS
2.5 3.29 (1.40-7.81) .01*
0 n/a NS
3.4 3.06 (1.26-7.54) .02*
NS, not significant.ularThis literature suggests that AAA patients might be strati-
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moderate, and prohibitive risk for EVAR.
Of the tested scoring systems, the M-LS and the M-
CSS both support risk discrimination with EVAR in our
database. Using the cut point of 11.8, low-risk patients
have a predicted mortality of 0.6%, whereas high-risk pa-
tients have a mortality of 3.8%. The M-CSS defines similar
groups: mortality rates at a cut point of 9 are 0% for low risk
and 3.7% for high risk.
Patients defined at high risk for EVAR in our popula-
tion still had a perioperative mortality of 4%. This fits
more with the US IDE high-risk cohort than with the
EVAR-2 population. As a result, although statistically sig-
nificant, our definition of a high-risk group for EVAR may
not be clinically meaningful: we cannot use these scoring
systems to define who might have a predictably poor out-
come from EVAR.
This study’s findings are limited by several factors. As a
retrospective study, objective definition of medical risk was
not assigned before operation. It is possible that poor
anatomy for EVAR is an important confounder in poor
outcome for open repair. A clear scenario is the juxtarenal
aneurysm, which has been shown to have poorer out-
come.18 Although our database did not document clamp-
ing above the renal arteries, the presence of a juxtarenal
aneurysm was noted with which clamping tended to be
suprarenal. Together these comprised 34 patients, of which
two died in the perioperative period (5.8% mortality).
We do not believe that these potential anatomic differ-
ences invalidate the relationship between medical comor-
bidity and outcome with method of repair. If we consider
the lowest medical risk subgroup, it is hard to conceive how
poor anatomy for EVAR confounds toward improved out-
come with open repair. Anatomic exclusion from EVAR is
more of a concern in the high-risk open repair outcome
data. However even here, comorbidity—not anatomy—
likely played an overriding role. An important step toward
supporting this impression would be to retrospectively
apply one of the scoring systems to the patient data from
the large randomized trials because all patients enrolled
were anatomic EVAR candidates.
Another limitation is the relatively small number of
deaths in the EVAR group as a whole. As a result, regres-
sion analysis in this data set could not confirm the associa-
tion between score and mortality risk. The small number of
deaths may predispose to a type 2 error in data interpreta-
tion. As a consequence, although it appears that the GAS
has no predictive ability in the EVAR data set, this is not
conclusively proven by this study. Indeed, given the results
of the EUROSTAR analysis,16 our lack of findings most
likely reflect inadequate power. Conversely, there may be a
role for cautious interpretation of the positive results of the
ROC analysis with the EVAR data for the M-LS and the
M-CSS. Overall, our data set suggests a utility of these
scores for defining operative risk with EVAR, but applica-
tion to a larger data set may allow for clarification of groups
that are at low, moderate, and prohibitive risk for aneurysm
repair.Another possible concern is the large proportion of
aortouniiliac grafts in this series. This is not a reflection of
anatomy that is not amenable to bifurcated graft placement
in most cases; rather, it has largely come about as a result of
physician preference. In our experience, aortouniiliac en-
dografts are simpler to plan and have fewer possibilities for
limb disconnect, and the femoral crossover confers no
increase in thrombosis risk.
CONCLUSION
Taking all patients together, a cursory assessment of the
EVAR-1 trial seemed to suggest that both open repair and
EVAR are equivalent options viewed from the standpoint
of 4-year follow-up. This report is a first attempt at dispel-
ling this simplification. It is initial support for our hypoth-
eses that criteria can be defined by which a subgroup of
patients who are high risk for open aneurysm repair—but
low risk for EVAR—can be objectively defined, and con-
versely, that another subgroup for whom EVAR confers no
major mortality advantage over open repair, even in the short
term, can also be identified. Given the retrospective nature
of this analysis, our study cannot conclusively prove these
hypotheses; however, it aims to set some objective param-
eters that would be required of a prospective trial that may.
In an era where medical cost containment is evermore
important, defining populations that might truly benefit
from more advanced, expensive, and less proven technol-
ogy is a necessity.
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Risk factor Class
Diabetes 0 none
1 adult onset, diet controlled
2 adult onset, insulin controlled
3 juvenile onset
Tobacco use 0 none
1 non current, but smoked in last 10 years
2 current, less than 1 pack/day
3 current, greater than 1 pack/day
Hypertension 0 none
1 easily controlled with 1 drug
2 controlled with 2 drugs
3 requires 2 drugs or uncontrolled
Hyperlipidemia 0 cholesterol/triglycerides within normal limits for age
1 mild elevation, controlled by diet
2 types II, III, IV, requiring strict dietary control
3 requiring dietary and drug control
Cardiac status 0 asymptomatic, normal ECG
1 asymptomatic, remote MI by history (6 months), occult MI by ECG
2 stable angina, controlled ectopy or asymptomatic arrhythmia, drug compensated CHF
3 unstable angina, symptomatic or poorly controlled ectopy/arrhythmia, poorly compensated CHF,
MI 6 months
Carotid disease 0 no symptoms, no bruit, no evidence of disease
1 asymptomatic, but evidence of disease
2 transient or temporary stroke
3 completed stroke with permanent neurologic deficit
Renal Status 0 no known renal disease, serum creatinine level 1.5 mg/dL
1 creatinine 1.5 to 3.0 mg/dL
2 creatinine 3.0 to 6.0 mg/dl, creatinine clearance 15 to 30 mL/min
3 creatinine greater than 6.0 mg/dl, creatinine clearance 15 mL/min or on dialysis or with transplant
Pulmonary status 0 asymptomatic, normal chest x-ray film, PFTs  20% of predicted,
1 asymptomatic or mild dyspnea on exertion, mild x-ray parenchymal changes, PFTs 65% to 80% of predicted
2 between 1 and 3
3 vital capacity less than 1.85 L, FEV1 less than 1.2 L or less than 35% of predicted, PCO2 45 mm Hg,
supplemental oxygen use necessary or pulmonary hypertension
ECG, Electrocardiogram; MI, myocardial infarction; PFTs, pulmonary function tests.
APPENDIX 2 (online only). Modifications to Risk factor definitions with Glasgow Aneurysm Score and Leiden Score
Scoring system Original risk factors Modified risk factor
Glasgow Aneurysm Score Renal failure Renal failure
● History of acute or chronic renal failure ● Creatinine 1.5 mg/dL (135 mmol/L)
● Creatinine 1.7 mg/dL (150 mmol/L)
● BUN 56 mg/dL (20 mmol/L)
Leiden Score Cardiac Comorbidity Cardiac Comorbidity
a. History of MI a. Asymptomatic, remote MI by history (6 months),
occult MI by ECG (3 points)● Documented history of MI regardless of ECG
findings (3 points)
b. Congestive heart failure b. Stable angina, controlled ectopy, asymptomatic
arrhythmia, or drug compensated CHF (8 points)● Cardiogenic pulmonary edema and/or jugular
venous distension
● Presence of a gallop rhythm (8 points)
c. ECG ischemia
● ST segment depression 2 mm on standard
resting ECG (8 points)
Renal Failure Renal failure
● Pre-op creatinine 1.8 mg/dL (160 mmol/L) ● Pre-op creatinine 1.5 mg/dL (135 mmol/L)
BUN, Blood urea nitrogen; MI, myocardial infarction; ECG, electrocardiogram; CHF, congestive heart failure.
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comorbidity grading system
Score Description of score
Major components
Cardiac status
0 Asymptomatic, with normal electrocardiogram
1 Asymptomatic but with either remote myocardial infarction by history (6 months), occult myocardial infarction
by electrocardiogram, or fixed defect on dipyridamole thallium or similar scan
2 Any one of the following: stable angina, no angina but significant reversible perfusion defect on dipyridamole
thallium scan, significant silent ischemia (1% of time) on Holter monitoring, ejection fraction 25% to 45%,
controlled ectopy or asymptomatic arrhythmia, or history of congestive heart failure that is now well
compensated
3 Any one of the following: unstable angina, symptomatic or poorly controlled ectopy/arrhythmia (chronic/
recurrent), poorly compensated or recurrent congestive heart failure, ejection fraction less than 25%,
myocardial infarction within 6 months
Pulmonary status
0 Asymptomatic, normal chest radiograph, pulmonary function tests 20% of predicted
1 Asymptomatic or mild dyspnea on exertion, mild chronic parenchymal radiograph changes, pulmonary
function tests 65% to 80% of predicted
2 Between 1 and 3
3 Vital capacity 1.85 L, FEV1 1.2 L or 35% of predicted, maximal voluntary ventilation 50% of predicted,
PCO2 45 mm Hg, supplemental oxygen use medically necessary, or pulmonary hypertension
Renal status
0 No known renal disease, normal serum creatinine level
1 Moderately elevated creatinine level, as high as 2.4 mg/dL
2 Creatinine level, 2.5 to 5.9 mg/dL
3 Creatinine level 6.0 mg/dL, or on dialysis or with kidney transplant
Minor components
Hypertension
0 None (cutoff point, diastolic pressure usually 90 mm Hg)
1 Controlled (cutoff point, diastolic pressure usually 90 mm Hg) with 1 drug
2 Controlled with 2 drugs
3 Requires 2 drugs or is uncontrolled
Age (years)
0 55
1 55-69
2 70-79
3 80
FEV1, Forced expiratory volume in 1 second.
APPENDIX 4 (online only). Predicted mortality of open repair patients using Leiden Score conversion algorithm
Predicted mortality (%) Observed mortality (%)
0-2 0
2-5 3.8
5-10 8.7
10 11.9
